21 CFR 11 Overview of the Final Document and its New Scope Ludwig Huber - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

21 CFR 11 Overview of the Final Document and its New Scope
Ludwig Huber
This article provides an overview of Rule 21 CFR Part 11's key requirements and its new, narrower scope.


Pharmaceutical Technology


For example, the regulation, earlier draft guidance documents, and early interpretations from FDA defined an electronic record as, "any combination of text, graphics, data, audio, pictorial, or other information representation in digital form that is created, modified, maintained, archived, retrieved, or distributed by a computer system" (1, Par. 11.1 [b]). But, the rule makes no distinction among the types of records or their criticality.

FDA requested Part 11 compliance for all such records that were generated or stored on a computer and could ask for such records at inspections. With this very broad interpretation, full implementation was very expensive and for some applications, it was impractical. In some cases, companies decided to keep paper records because of the anticipated additional complexity and cost involved with implementing the technical control required by the rule. This outcome clearly was not the original intent and spirit of the rule which was issued to protect public health and enable new technology to be used.

With the release of the draft guidance on scope and application of Part 11 in Feb. 2003 (5), FDA promoted a new, narrower approach. With the final guidance released on Sept. 3, 2003 and FDA's announcement to reexamine Part 11 and initiate a new rule-making process, this narrower approach became official and probably will be the basis for an updated regulation in the future.

The guidance states that Part 11 applies when:
  • the record is required by a predicate rule (e.g., electronic batch records for 21 CFR Part 211 and electronic training records in 21 CFR Part 58);
  • the electronic records are used to demonstrate compliance with a predicate rule (e.g., electronic training records for compliance with 21 CFR Part 211).

Part 11 applies in one or both of the following situations:

  • when electronic records are used instead of paper;
  • when persons make printouts but still rely on the electronic records to perform regulated activities.


Figure 1: Steps to determine whether records are within the scope of Part 11 (7).
Figure 1 illustrates the decision flow to determine which records fall under the scope of Part 11. This figure has been presented several times by FDA staff Part 11 experts. First, we check if the record is required by and can demonstrate compliance with the predicate rule.

Next, we determine if the record fits in the new, more-specific scope of Part 11. The main criterion is whether the record is maintained in electronic format in place of a paper format or in both electronic and paper formats, and whether people rely on the electronic records to perform regulated activities. A regulated activity is any activity required by an FDA regulation. For example, analytical test results must be recorded according to FDA's 21 CFR Part 211. In this case, the regulated activity is not limited to signing the record (e.g., a paper printout of an electronic record). It also includes all steps from data acquisition and evaluation.

Finally, we make a risk assessment of the criticality of the records and document the result. Based on the outcome, appropriate Part 11 controls are implemented.

The final criteria is to evaluate the risk the record has on product quality and data integrity. Examples of high-risk records are electronic batch records and analytical records of final product testing. Errors at this stage will not be identified and cannot be recovered before the product ships to the market. An example of low-risk records are electronic planning documents such as cleaning or maintenance schedules. Electronic standard operating procedures could fall into the medium- or low-risk category, depending on the procedure's effect on product quality. The International Society for Pharmaceutical Engineering has published a list of such risk classifications (6).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here